Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancer

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences